saikosaponin d has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dong, Q; Feng, J; Jiang, X; Li, Y; Liu, M; Nik Nabil, WN; Song, Z; Xi, Z; Xu, H; Zhou, H | 1 |
| Cao, L; Gao, H; Qu, S; Yang, J; Yao, M; Zhang, L | 1 |
2 other study(ies) available for saikosaponin d and Cancer of Prostate
| Article | Year |
|---|---|
Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt | 2023 |
Saikosaponin‑d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; G1 Phase Cell Cycle Checkpoints; Humans; Male; Membrane Potential, Mitochondrial; Oleanolic Acid; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Saponins; Tumor Suppressor Protein p53; Up-Regulation | 2014 |